Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates

Minicozzi, Pamela; Cassetti, Tiziana; Vener, Claudia; Sant, Milena

doi:10.1016/j.canep.2018.04.011

Cited by 35 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Older age was given a greater weighting in the RESP, and therefore, the incidence was higher if calculated with the RESP than with the ESP, which represents the age shift that is occurring in Europe. An analysis of incidence of PDAC across Europe described an age-standardised incidence, based on the ESP, between 12 (UK/Ireland and southern Europe) to 15 (northern and eastern Europe) per 100.000 persons per year between 2000 and 2007 [43]. The incidence in our population was lower in this period with 8e9 per 100.000 person annually.…”

Section: Cox Regressionmentioning

confidence: 66%

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Latenstein

Geest

Bonsing

et al. 2020

European Journal of Cancer

116

View full text Add to dashboard Cite

show abstract

Section: Cox Regressionmentioning

confidence: 66%

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Latenstein

Geest

Bonsing

et al. 2020

European Journal of Cancer

116

View full text Add to dashboard Cite

show abstract

“…Development of the iCCA is a multistep process of dysplastic and in situ lesions leading to cancer, which can be sometimes mistaken for intrahepatic metastases of gastric or pancreatic primary carcinoma [17]. BTCs are more prevalent in males than in females, and the risk of the development increases with age, with the majority of cases being diagnosed in patients over 75 years old [2]. Multiple lifestyle and diet risk factors have been described, including smoking, alcohol consumption, and aflatoxin contamination [3,4].…”

Section: Cholangiocarcinoma (Cca)mentioning

confidence: 99%

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine

Malenica

Donadon

Lleo

2020

Cancers

View full text Add to dashboard Cite

Biliary tract cancers (BTCs) are a group of rare cancers that account for up to 3–5% of cancer patients worldwide. BTCs include cholangiocarcinoma (CCA), gallbladder cancer (GBC), and ampulla of Vater cancer (AVC). They are frequently diagnosed at an advanced stage when the disease is often found disseminated. A late diagnosis highly compromises surgery, the only potentially curative option. Current treatment regimens include a combination of chemotherapeutic drugs gemcitabine with cisplatin that have a limited efficiency since more than 50% of patients relapse in the first year. More recently, an inhibitor of fibroblast growth factor receptor 2 (FGFR2) was approved as a second-line treatment, based on the promising results from the NCT02924376 clinical trial. However, novel secondary treatment options are urgently needed. Recent molecular characterization of CCA and GBC highlighted the molecular heterogeneity, etiology, and epidemiology in BTC development and lead to the classification of the extrahepatic CCA into four types: metabolic, proliferating, mesenchymal, and immune type. Differences in the immune infiltration and tumor microenvironment (TME) have been described as well, showing that only a small subset of BTCs could be classified as an immune “hot” and targeted with the immunotherapeutic drugs. This recent evidence has opened a way to new clinical trials for BTCs, and new drug approvals are highly expected by the medical community.

show abstract

“…Europe comes in second place regarding pancreatic cancer incidence (number of new patients), behind the Western Pacific region, and the estimated highest age-standardised incidence rates per 100,000 individuals exist in Europe (9.3 per 100,000 males and 6.3 per 100,000 females) [1]. Estimated incidence rates in each of the sexes separately, in the different world regions, showed that pancreatic cancer rates are highest among males in Central and Eastern Europe (9.9 per 100,000 men), namely Latvia and the Republic of Moldova, with a rate of 15.3 per 100,000 males in both countries [10]. The highest incidence rates among women were in Western Europe with a rate of 7.2 per 100,000 women.…”

Section: Incidencementioning

confidence: 99%

Pancreatic cancer trends in Europe: epidemiology and risk factors

Hawksworth¹,

Hales²,

Martínez³

et al. 2019

View full text Add to dashboard Cite

Pancreatic cancer is the 12 th most common cancer worldwide and the seventh leading cause of cancer-related deaths worldwide. However, it is the seventh most common cancer in Europe. The estimated number of cases of pancreatic cancer worldwide in 2018 was 458,918 with a male to female ratio of 1:1.13. Among those 458,918 patients, 132,559 cases were found in Europe. Rates of pancreatic cancer are 3-4 times higher in the developed world. With incidence and mortality rates being very close, pancreatic cancer is considered one of the deadliest of all cancers. Lifestyle in developed nations, including the rise in physical inactivity and obesity, tobacco smoking, consumption of alcohol, dietary factors, and occupational exposures, may be responsible for the increased incidence of pancreatic cancer. Updated statistics on the epidemiology of pancreatic cancer along with a better understanding of the risk factors are essential for the primary prevention of this disease. Streszczenie Rak trzustki jest dwunastym najczęściej występującym nowotworem i siódmą główną przyczyną zgonów związanych z rakiem na świecie. Jest to także siódmy najczęściej występujący nowotwór w Europie. Liczba przypadków raka trzustki na świecie w 2018 roku wynosiła 458 918, przy stosunku mężczyzn do kobiet 1 : 1,13. W Europie stwierdzono 132 559 przypadków. Występowanie raka trzustki jest 3-4 razy częstsze w krajach rozwiniętych. Ponieważ częstość występowania i śmiertelność są bardzo zbliżone, rak trzustki jest uważany za jeden z najbardziej śmiertelnych nowotworów. Styl życia w krajach rozwiniętych, w tym brak aktywności fizycznej i otyłość, palenie tytoniu, spożywanie alkoholu, czynniki dietetyczne i narażenie zawodowe, może odpowiadać za zwiększoną częstość występowania raka trzustki. Zaktualizowanie statystyki dotyczącej raka trzustki oraz lepsze zrozumienie czynników ryzyka są niezbędne do zapobiegania tej chorobie.

show abstract

Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates

Cited by 35 publications

References 24 publications

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine

Pancreatic cancer trends in Europe: epidemiology and risk factors

Contact Info

Product

Resources

About